Published: 19. August, 2022

Cessatech A/S today releases its results for the period 1 April – 30 June…

Cessatech A/S today releases its results for the period 1 April – 30 June 2022. The second quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports. The Company is progressing with planned activities: Recruitment of trial 0206 was completed (a trial to investigate the pharmacokinetics in children aged 1-17 undergoing elective surgical procedures) and finally regulatory approval was received and thereby a green light to initiate recruitment of the pivotal trial 0205 with CT001, a randomised double-blind placebo controlled trial with 220 patients in adult following impacted mandibular third molar extraction. First patient is expected during Q3 2022

Cessatech_Q2-2022 Report

During the second quarter of 2022 we finalised the recruitment of our Phase 2 trial 0206, the pharmacokinetic study with CT001 and very importantly, obtained regulatory approval for our pivotal trial 0205, a randomised double-blind placebo controlled study with 220 patients. We expect to dose the first patients shortly, bringing us in a selected group of companies in late stage development. We look forward to a very exciting year for the Company with a rich news flow“ says Jes Trygved, CEO